Expression of MMP-2, MT1-MMP, and TIMP-2 mRNA in Breast Carcinomas.
- Author:
Dong Won KIM
1
;
So Young JIN
;
Dong Wha LEE
Author Information
1. Department of Pathology, Soonchunhyang University Hospital, Seoul, Korea. pathol@hosp.sch.ac.kr
- Publication Type:Original Article
- Keywords:
Breast Neoplasms;
Gelatinase A;
Tissue Inhibitor of Metalloproteinase 2;
Membrane;
type 1 Matrix Metalloproteinase;
In Situ Hybridization
- MeSH:
Breast Neoplasms*;
Breast*;
Carcinoma, Ductal;
Carcinoma, Intraductal, Noninfiltrating;
Humans;
In Situ Hybridization;
Matrix Metalloproteinase 14*;
Matrix Metalloproteinase 2;
Membranes;
RNA, Messenger*;
Tissue Inhibitor of Metalloproteinase-2*
- From:Korean Journal of Pathology
2003;37(6):400-406
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The activation of proMMP-2 is induced by membrane type 1-matrix metalloproteinase (MT1-MMP), but inhibited by tissue inhibitors of matrix metalloproteinase type 2 (TIMP-2). This study was carried out to establish the pattern of mRNA expression of MMP-2, MT1-MMP, and TIMP-2 in breast carcinomas. METHODS: Seventy-nine cases of invasive ductal carcinoma, 10 of ductal carcinoma in situ, and 10 of fibrocystic disease as a control were analysed for the expression of MMP-2, MT1-MMP, and TIMP-2 mRNA, using in situ hybridization. Correlations of the results with the clinical stage, tumor size, nodal status, and nuclear grade were analysed. RESULTS: The expression rates of MMP-2, MT1-MMP, and TIMP-2 mRNA in invasive ductal carcinoma were 68%, 73%, and 56%, respectively. They were localized to both stromal and tumor cells, but mainly in the latter. The MMP-2 mRNA expression was significantly correlated with the clinical stage (p < 0.05), while the expression of TIMP-2 mRNA was inversely correlated with clinical stage and tumor size(p < 0.05). Significant positive correlations between MMP-2 and MT1-MMP expressions, along with inverse relationships between MMP-2 and TIMP-2, and between TIMP-2 and MT1-MMP, were also found. CONCLUSIONS: MMP-2 and TIMP-2 mRNA expressions might be useful as one of a range of prognostic parameters in breast carcinoma patients.
